PolyPid (NASDAQ:PYPD – Get Free Report) and Ubiquitech Software (OTCMKTS:UBQU – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Valuation and Earnings
This table compares PolyPid and Ubiquitech Software”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PolyPid | N/A | N/A | -$34.17 million | ($1.48) | -3.37 |
| Ubiquitech Software | N/A | N/A | N/A | ($0.00) | N/A |
Insider and Institutional Ownership
26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares PolyPid and Ubiquitech Software’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PolyPid | N/A | -311.08% | -150.83% |
| Ubiquitech Software | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent recommendations for PolyPid and Ubiquitech Software, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PolyPid | 1 | 0 | 3 | 0 | 2.50 |
| Ubiquitech Software | 0 | 0 | 0 | 0 | 0.00 |
PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 127.12%. Given PolyPid’s stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than Ubiquitech Software.
Summary
PolyPid beats Ubiquitech Software on 5 of the 9 factors compared between the two stocks.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
About Ubiquitech Software
Ubiquitech Software Corp. develops Internet marketing and sales software solutions in the United States. The company's Internet sales technologies include Blue Crush Monetization System that creates advertising platforms and improves existing platforms to increase sales; InternationalFortune.com, a lead generation portal for currency trading companies, hedge funds, and other asset managers worldwide; and Blue Crush Connect, a social network that rewards and incentivizes customers. It also operates AffiliateCashExpress.com and NeedFunded.com. Ubiquitech Software Corp. was incorporated in 2007 and is based in Denver, Colorado.
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
